SureTrader Advertisement Advertisement Advertisement
Home > Boards > US Listed > Biotechs >

MultiCell Technologies (MCET)

Add MCET Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator MyDogBuster, Dip66, HorseShoe Man
Search This Board:
Last Post: 10/8/2015 2:57:25 PM - Followers: 563 - Board type: Free - Posts Today: 0

MultiCell Technologies, Inc. (MCET)

(U.S. Reporting: SEC Filer) 

Outstanding shares 5,000,948,700 as of Jul 8, 2015 

Office: (401) 762-0045  |  Email:

(This "Intro Box" is NOT maintained by MultiCell Technologies and is intended solely as a quick information source on ihub.  For more detailed, up-to-date information on MultiCell Technologies,  please go the company website.)




Therapeutic Pipeline

MultiCell Technologies’ portfolio of lead drug candidates is in various stages of preclinical and clinical development:

MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial.
MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.
MCT-475, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.
MCT-485, a discovery stage dsRNA therapeutic candidate for the treatment of certain cancers.

 Therapeutic Candidate  


    Discovery Optimization    

    Preclinical Development    

    Phase 1    

    Phase 2/b   

    Phase 3    



yes yes yes yes  



yes yes      



yes yes      



yes yes      

Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.

MultiCell Technologies, Inc. Corporate Headquarters

68 Cumberland Street, Suite 301
Woonsocket, RI 02895

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.

Our therapeutic development platform relies on several patented technologies used to: (i) isolate, characterize and differentiate stem cells from human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.

Our most advanced lead drug candidate, MCT-125, is an oral small molecule drug combination which targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF). Primary multiple sclerosis-related fatigue (PMSF) affects over 70% of all persons with multiple sclerosis (MS). MCT-125 has demonstrated efficacy in a 138 patient Phase 2a clinical trial for the treatment of PMSF.

While significant progress has been made in developing cancer therapies that result in tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal. MultiCell is also developing novel therapeutics for the treatment of cancer. MCT-465, MCT-475 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented therapeutic antibody and synthetic dsRNA technologies. MCT-465, a potent immune enhancer, is indicated as an cancer adjuvant therapy alone or combined with currently available or novel therapies. MCT-465 can also be used with our MCT-475 antibody therapeutic for the treatment of various cancers such as breast carcinoma. MCT-485, a cytotoxic agent, is a novel synthetic dsRNA with therapeutic properties distinct from those of MCT-465, and is indicated for the treatment of certain cancers. MCT-465 is in early-stage preclinical development, and MCT-475 and MCT-485 are in the discovery optimization stage of development.

The role liver stem cells play in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. MultiCell is developing therapeutic product opportunities specifically targeting the treatment of hepatocellular carcinoma and intrahepatic bile duct cancer by leveraging our synthetic dsRNA and antibody therapeutic platforms against cancer stem cells. MultiCell owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), and several corresponding issued and pending patents and patent applications related to the isolation and differentation of liver stem cells.

Find us on Google Maps  

 Management and Board of Directors

Barbara (Corbett) Newmin - Investor Relations

W. Gerald Newmin, Chairman and Chief Executive Officer

Dr. Steve Chang Ph. D., Director

Grant Miller, Director


Alan Tuchman, M.D.

Thomas A. Page, Director

Edward Sigmond, Director


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MCET News: Statement of Changes in Beneficial Ownership (4) 07/30/2015 06:10:34 PM
MCET News: Statement of Changes in Beneficial Ownership (4) 07/30/2015 06:09:13 PM
MCET News: Statement of Changes in Beneficial Ownership (4) 07/30/2015 06:07:11 PM
MCET News: Statement of Changes in Beneficial Ownership (4) 07/30/2015 06:05:40 PM
MCET News: Quarterly Report (10-q) 07/16/2015 06:06:29 AM
#34376  Sticky Note MultiCell Technologies, Inc. OTCQB TraderpennyX 04/03/14 03:57:31 AM
#40857   I think they actually need to do something simon wagstaff 10/08/15 02:57:25 PM
#40856   Well the increase in the number of shares The dead cat bouncer 10/08/15 02:23:35 PM
#40855   Its more like sup105 10/07/15 11:14:03 PM
#40854   Haha ya its like he is transfering money sup105 10/07/15 03:21:15 PM
#40853   Okay they made some money and there will The dead cat bouncer 10/07/15 02:04:20 PM
#40852   What is not funny that the money come ferenc 10/07/15 12:26:28 PM
#40851   Here us catch ,Newmin owns 8 % of sup105 10/07/15 11:10:16 AM
#40850   Did they ever come forth with any reasons stockshopper101 10/07/15 11:09:40 AM
#40849   Good analysis. MCET never started any trials, they simon wagstaff 10/07/15 09:55:00 AM
#40848   If a pharmaceutical company makes money then it HorseShoe Man 10/07/15 06:52:01 AM
#40847   If the company is now making money I Dip66 10/07/15 12:24:22 AM
#40846   I'm A newbee to this site so I'm stockshopper101 10/06/15 11:45:48 PM
#40845   Nothing is misleading people can read 10k for sup105 10/06/15 01:45:03 PM
#40844   "Hope Mcet pass the trial 2b," simon wagstaff 10/06/15 01:41:02 PM
#40843   Well at least Mcet staff salary is all sup105 10/06/15 01:07:45 PM
#40842   I think investors will flock back when this Dip66 10/06/15 12:53:35 PM
#40841   Come on baby! Bust loose and give HorseShoe Man 10/06/15 12:51:48 PM
#40840   Feeling like this is going to bust loose HorseShoe Man 10/06/15 12:31:35 PM
#40839   Someone's buying up all the 3's? Funny trading HorseShoe Man 10/06/15 12:24:04 PM
#40838   HUMMM? Did I say that already HorseShoe Man 10/06/15 12:12:16 PM
#40837   HMMM? HorseShoe Man 10/06/15 11:04:48 AM
#40836   16 millions buy / 17 million volume sup105 10/05/15 03:48:34 PM
#40835   Unless there is shortage of share which mcet sup105 10/05/15 01:22:41 PM
#40834   Volume dont really matter if everyone put order sup105 10/05/15 01:21:32 PM
#40833   No matter what the volume is the sock eshety 10/05/15 01:11:19 PM
#40832   "I'm tired of playing where's Waldo with you." simon wagstaff 10/04/15 08:10:15 AM
#40831   HorseShoe . . . bontooth 10/04/15 01:12:13 AM
#40830   She's up to something! Nice daily chart. At HorseShoe Man 10/03/15 05:26:53 PM
#40829   I'm tired of playing where's Waldo with you. mrroundtree 10/03/15 11:28:51 AM
#40828   This board really likes 10 year old news. simon wagstaff 10/03/15 09:05:47 AM
#40827   Mcet need pay some money to Pr company sup105 10/02/15 04:43:11 PM
#40826   Really hope your right this time but not ctvette2003 10/02/15 04:06:47 PM
#40825   I predict whoever is not in today will Dip66 10/02/15 03:05:39 PM
#40824   Wash rinse & repeat. Dipp you say exactly ctvette2003 10/02/15 02:11:58 PM
#40823   Ask: .0004$ something is up! Dip66 10/02/15 01:39:17 PM
#40822   Surprised nobody buy with monster news out etcetera 10/02/15 01:25:39 PM
#40821   MultiCell Immunotherapeutics, Inc. develops therapeutic products using stem mrroundtree 10/02/15 11:12:55 AM
#40820   MultiCell Immunotherapeutics, Inc. (MCIT) License Agreement. Oxis licensed Dip66 10/02/15 11:09:48 AM
#40819   Yes, the $500K turned into $171K with $220K simon wagstaff 10/02/15 08:54:51 AM
#40818   MCET said to "stay tuned"! Starting to think HorseShoe Man 10/02/15 07:32:50 AM
#40817   Check out my last post and you will The dead cat bouncer 10/01/15 01:24:52 PM
#40816   Read this: The dead cat bouncer 10/01/15 01:20:19 PM
#40815   so did I bontooth 10/01/15 12:45:59 AM
#40814   Tis is from the 10Q of OXIS at 8/14?2015 ferenc 09/30/15 05:30:49 PM
#40813   Something feels awfully wrong here. Time for Gerald Dip66 09/30/15 03:05:39 PM
#40812   Time for a emergency shareholders meeting and vote HorseShoe Man 09/30/15 01:14:29 PM
#40811   No, MCET is not making money. if they simon wagstaff 09/30/15 09:24:32 AM
#40810   There is no reason to print any more The dead cat bouncer 09/29/15 09:46:24 PM
#40809   I stopped worrying several years ago when MultiCell Dip66 09/29/15 02:41:28 PM
#40808   correction. . University of Pittsburg. bontooth 09/28/15 05:23:32 PM